Last reviewed · How we verify
NCT00826046
Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute Graft Versus Host Disease (GVHD)
trial testing Prochymal® in Graft-Versus-Host Disease. No longer available.
Quick facts
| Lead sponsor | Mesoblast, Inc. |
|---|---|
| Status | NO LONGER AVAILABLE |
| Study type | EXPANDED_ACCESS |
| Sites | 3 locations across United States |
Drugs / interventions tested
- Prochymal® — full drug profile →
Conditions studied
- Graft-Versus-Host Disease — all drugs for Graft-Versus-Host Disease →
Sponsor
Mesoblast, Inc. — full company profile →
Who can join
Adults 18 to 70, any sex, with Graft-Versus-Host Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This protocol allows for the treatment of patients, male and female, between the ages of 18 years and 70 years. Patients must have failed to respond to steroid treatment for Grade C-D acute GVHD.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity.
Stenger EO, Turnquist HR, Mapara MY, Thomson AW. · · 2012 · cited 89× · PMID 22403259 · DOI 10.1182/blood-2011-11-364091 -
Potential clinical applications of adult human mesenchymal stem cell (Prochymal®) therapy.
Patel AN, Genovese J. · · 2011 · cited 35× · PMID 24198531 · DOI 10.2147/sccaa.s11991
Verify or expand the search:
- PubMed search for NCT00826046
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Prochymal®
Trials testing the same drug.
- NCT01233960 — Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease · Phase 3 · completed
- NCT00877903 — Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI) · Phase 2 · completed
- NCT00562497 — Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acut · Phase 3 · completed
- NCT00482092 — Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease · Phase 3 · completed
- NCT00366145 — Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (G · Phase 3 · completed
Other recruiting trials for Graft-Versus-Host Disease
Currently open trials in the same condition.
- NCT06423131 — Prospective Clinical Trial for Children With TCRαβ Depleted vs Traditional Haplo Identicle HSCT · NA · recruiting
- NCT05675930 — A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transpl · Phase 2 · recruiting
- NCT00001529 — Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives · recruiting
Other Mesoblast, Inc. trials
Trials by the same sponsor.
- NCT02652130 — Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatme · Phase 3 · completed
- NCT02336230 — A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pedia · Phase 3 · completed
- NCT02032004 — Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure · Phase 3 · completed
- NCT01781390 — Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction · Phase 2 · completed
- NCT01233960 — Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00826046 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mesoblast, Inc.
- Last refreshed: 9 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00826046.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing